CRISPR Therapeutics (NASDAQ: CRSP), a gene editing-focused biotech, has made significant clinical and regulatory progress over the past five years.
However, over this period, the company has lagged broader equities.
CRISPR Therapeutics' shares have declined by about 47% since mid-October 2021, while the S&P 500 has gained almost 73%, as of writing.